Date Hour Room Track
28th November,2017 4:30 - 6:00 pm Salon Madrid 4 Track 3

What do these therapeutic funds bring to the companies and community of investors in terms of quality of expertise and specific network opportunities? Does the presence of focused therapeutic funding in the early stages ease the co-investment of more generalist funds?

James Peyer - Apollo Ventures
Christian Tidona - BioMed X
Jakob Loven - Nextech Invest
Michael Midmer - Zucara Therapeutics
Fabrice Aurousseau - PPRS Research
Philippe Pouletty - Truffle Capital

Continue your tour